Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$20.02M$20.02M−21.2% vs Q1 2020 Net Income-$52.61M-$52.61MN/M vs Q1 2020 EPS Diluted-$0.58-$0.58N/M vs Q1 2020 Operating Income-$52,114,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Free Cash Flowderived-$42,724,000N/M Margins · derivedOperating margin-260.3%−52.7 pt vs Q1 2020
Net margin-262.8%−59.8 pt vs Q1 2020
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end